#1263 Cardiovascular risk in systemic lupus erythematosus with and without lupus nephritis: a cross-sectional comparative study

Le résumé fourni par la source

Abstract Background and Aims Patients with systemic lupus erythematosus (SLE) have an increased cardiovascular risk (CVR) compared to the general population. Some studies have observed that a history of lupus nephritis (LN), even with preserved renal function, further increases CVR. Our objective is to compare and analyse whether there are differences in CVR in our sample of patients with SLE with and without a history of LN. Method A cross-sectional comparative study was conducted on 206 patients with SLE from our centre, in whom CVR was assessed using the SCORE2 and QRISK3 scores and carotid ultrasound for detecting atheromatous plaque. Patients were divided into two groups based on a history of LN, and differences were analysed using binary logistic regression with SPSS software. Results The main characteristics of the sample are presented in Table 1, along with results from univariate analysis and those adjusted for sex, disease duration, and renal function. No differences were found in univariate analysis for CV events or in the CVR assessment tools used. Differences were observed in hypertension (OR 2.043 [1.069–3.904], P = 0.031) and uricemia (OR 1.300 [1.044–1.617], P = 0.019) in the univariate model, with a trend toward significance in dyslipidaemia (with a protective OR for HDL 0.976 [0.954–0.997], P = 0.028); all of which were corrected after adjustment. C3 hypocomplementemia, high values of high-sensitivity CRP and ESR showed OR >1 in univariate analysis but were corrected after adjustment. Only native anti-DNA antibodies, positive at the time of the study, were significantly more frequent in patients with LN after adjustment (OR 2.463 [1.053–5.759], P = 0.038). Conclusion No significant differences were found in the regression model after adjusting for factors, scores, and CV risk assessment tests between SLE patients with and without a history of LN. In our sample, patients with LN were 2.4 times more likely to have positive anti-DNA antibodies.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.